Evicenter
P&T meetings

Zeleciment rostudirsen (z-rostudirsen)

Duchenne muscular dystrophy

Also known as DYNE-251
Manufacturer
Dyne Therapeutics
Regulatory submission
BLA submitted May 2026
Last updated
78 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionEpidemiology

Prevalence of Duchenne muscular dystrophy

3 evidence topics · 4 sources

U.S. population estimates

“~12,000 US DMD population” (opens the source at this quote in a new tab)

“~1,600 US Exon 51 skip amenable DMD” (opens the source at this quote in a new tab)

Global male prevalence

“The pooled global DMD prevalence was 7.1 cases (95% CI: 5.0-10.1) per 100,000 males” (opens the source at this quote in a new tab)

Updated exon-skipping applicability

“Exon 51 was the most relevant target and was applicable for 10.6% of all mutations and 17.2% of large deletions.” (opens the source at this quote in a new tab)